Previous Article | Next Article ![]()
J. Virol., Apr 1995, 2297-2305, Vol 69, No. 4
JE Gairin, H Mazarguil, D Hudrisier and MB Oldstone
Infection with lymphocytic choriomeningitis virus induces the generation of
CD8+ cytotoxic T lymphocytes (CTL). In the H-2b mouse, this cellular immune
response is directed against three viral structural epitopes (GP1, GP2, and
NP) presented by the major histocompatibility complex (MHC) class I H-2Db
molecules. This study was undertaken to delineate which sequence of each of
these three epitopes is optimal for MHC binding and CTL recognition. The
first step was to synthesize the relevant peptides truncated at the N or C
terminus and flanking the crucial H-2Db-anchoring Asn residue in position
5. These peptides were then tested (i) for their binding properties in two
H-2Db-specific assays with viable cells (upregulation of H-2Db expression
on the surface of RMA-S cells and competition against the Db-restricted
peptide 125I-gp276-286 on T2-Db cells) and (ii) for their abilities to
sensitize H-2b target cells for CTL lysis in vitro. For optimal antigenic
presentation, all three epitopes required the MHC-anchoring Asn residue at
position 5 of their sequences. The results clearly and unambiguously
delineated optimal lengths for two of the epitopes and two options for the
third. NP appeared as a conventional 9-amino-acid (aa)-long peptide,
np396-404 (FQPQNGQFI). GP2 was defined as a longer peptide (11 aa),
gp276-286 (SGVENPGGYCL). Characterization of the GP1 epitope was more
complex: the 9-aa-long peptide gp33-41 (KAVYNFATC) and the
carboxyl-extended 11- aa-long peptide gp33-43 (KAVYN FATCGI) were both
established as possible optimal sequences depending on the cell line used
to test binding and lysis.
Copyright © 1995, American Society for Microbiology
Optimal lymphocytic choriomeningitis virus sequences restricted by H- 2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes
Laboratoire de Pharmacologie et Toxicologie Fondamentales, Centre National de la Recherche Scientifique, Toulouse, France.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|